Seasonal Influenza Vaccine Supply for the U.S. 2017-2018 Influenza Season
On This Page
- How much influenza vaccine is projected to be available for the 2017-2018 influenza season?
- How much thimerosal-free influenza vaccine is expected to be available for the 2017-2018 season?
- How much quadrivalent (four-component) vaccine is expected to be available for the 2017-2018 season?
- Can I still buy influenza vaccine for the 2017-2018 season?
- What can we anticipate in terms of the timing of vaccine availability for the 2017-2018 season?
- Are all influenza vaccines the same?
- Egg Allergy
- Where can I find information about vaccine supply?
More of the latest information is available on the total distribution of influenza vaccine doses for the 2017-2018 season.
Flu vaccine is produced by private manufacturers, so supply depends on manufacturers. Vaccine manufacturers originally projected that as many as 151 million to 166 million doses of injectable flu vaccine (i.e., inactivated and recombinant flu vaccines) would be made available for the 2017-2018 season.
For the 2017-2018 season, manufacturers will produce influenza vaccines containing thimerosal and some vaccines that do not contain thimerosal.
Approximately 130 million doses of thimerosal-free or preservative-free influenza vaccine will be produced for the 2017-2018 flu season.
How much quadrivalent (four-component) vaccine is expected to be available for the 2017-2018 season?
For the 2017-2018 season, manufacturers will produce both trivalent (three-component) and quadrivalent (four-component) flu vaccines.
Approximately 119 million doses of quadrivalent flu vaccines will be produced for the 2017-2018 season.
Influenza vaccine pre-booking typically occurs between January and March, though most preparations of vaccine should still be available for purchase. Providers should contact distributors and local vendors about remaining supply. Information about manufacturers and distributors who still have influenza vaccine available for sale can be found at http://www.preventinfluenza.org/ivats/.
The timing of vaccine availability depends on when production is completed. Some influenza vaccine shipments have already begun and will continue throughout August, September, October, and November until all of the vaccine is distributed.
Different influenza vaccine preparations have different indications as licensed by the FDA. See the table below for an overview of these indications.
The recommendations for vaccination of people with egg allergies were changed for 2016-2017 flu season.
People with egg allergies can receive any licensed, recommended age-appropriate influenza vaccine and no longer have to be monitored for 30 minutes after receiving the vaccine. People who have severe egg allergies should be vaccinated in a medical setting and be supervised by a health care provider who is able to recognize and manage severe allergic conditions.
Information about vaccine supply is available on the CDC influenza web site.
TABLE 1. Influenza vaccines — United States, 2017–2018 influenza season
TABLE 2. Contraindications and precautions to the use of influenza vaccines — United States, 2017–2018 influenza season*
COMING SOONTop of Page
- Page last reviewed: August 16, 2017
- Page last updated: August 30, 2017
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs